Literature DB >> 18455200

Intracellular localization of lipoplexed siRNA in vascular endothelial cells of different mouse tissues.

Manuela Aleku1, Gerald Fisch, Kristin Möpert, Oliver Keil, Wolfgang Arnold, Jörg Kaufmann, Ansgar Santel.   

Abstract

Liposomally formulated siRNA can be used for RNAi applications in vivo. Intravenous bolus administration of lipoplexed siRNA has been shown to reduce gene expression in the vascular endothelium. Here, we applied immunofluorescence staining for different endothelial markers (PECAM-1, CD34, laminin) on paraffin sections to compare the respective expression pattern with the intracellular localization of intravenously administered, fluorescently labeled siRNA (siRNA-Cy3-lipoplex). By confocal microscopy, lipoplexed siRNA-Cy3 was detected inside vascular endothelial cells in vivo, which where identified with co-staining of endothelial markers. Consequently, the finding of intracellular siRNA uptake by vascular endothelial cells correlated with RNAi based specific protein reduction in situ as revealed by PECAM-1 specific immunofluorescence staining in lung tissue sections. Therefore, by using a cell biological approach these in situ data emphasize the functional uptake of liposomal siRNA molecules in vascular endothelial cells of different mouse tissues as indicated in our previous molecular study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18455200     DOI: 10.1016/j.mvr.2008.02.004

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  10 in total

1.  A novel method for conjugating the terminal amine of peptide ligands to cholesterol: synthesis iRGD-cholesterol.

Authors:  Matthew G Fete; Jamie L Betker; Richard K Shoemaker; Thomas J Anchordoquy
Journal:  Ther Deliv       Date:  2019-01

2.  Nonadditive Effects of Repetitive Administration of Lipoplexes in Immunocompetent Mice.

Authors:  Jamie L Betker; Thomas J Anchordoquy
Journal:  J Pharm Sci       Date:  2016-11-22       Impact factor: 3.534

3.  Local tissue expression of the cell death ligand, fas ligand, plays a central role in the development of extrapulmonary acute lung injury.

Authors:  Rajan K Thakkar; Chun-Shiang Chung; Yaping Chen; Sean F Monaghan; Joanne Lomas-Neira; Daithi S Heffernan; William G Cioffi; Alfred Ayala
Journal:  Shock       Date:  2011-08       Impact factor: 3.454

4.  The role and source of tumor necrosis factor-α in hemorrhage-induced priming for septic lung injury.

Authors:  Joanne Lomas-Neira; Mario Perl; Fabienne Venet; Chun-Shiang Chung; Alfred Ayala
Journal:  Shock       Date:  2012-06       Impact factor: 3.454

Review 5.  Personalized cancer approach: using RNA interference technology.

Authors:  John Nemunaitis; Donald D Rao; Shi-He Liu; F Charles Brunicardi
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

6.  In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight.

Authors:  James E Dahlman; Carmen Barnes; Omar Khan; Aude Thiriot; Siddharth Jhunjunwala; Taylor E Shaw; Yiping Xing; Hendrik B Sager; Gaurav Sahay; Lauren Speciner; Andrew Bader; Roman L Bogorad; Hao Yin; Tim Racie; Yizhou Dong; Shan Jiang; Danielle Seedorf; Apeksha Dave; Kamaljeet S Sandu; Matthew J Webber; Tatiana Novobrantseva; Vera M Ruda; Abigail K R Lytton-Jean; Christopher G Levins; Brian Kalish; Dayna K Mudge; Mario Perez; Ludmila Abezgauz; Partha Dutta; Lynelle Smith; Klaus Charisse; Mark W Kieran; Kevin Fitzgerald; Matthias Nahrendorf; Dganit Danino; Rubin M Tuder; Ulrich H von Andrian; Akin Akinc; Avi Schroeder; Dipak Panigrahy; Victor Kotelianski; Robert Langer; Daniel G Anderson
Journal:  Nat Nanotechnol       Date:  2014-05-11       Impact factor: 39.213

7.  Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease.

Authors:  Olivia Simmons; Phillip B Maples; Neil Senzer; John Nemunaitis
Journal:  ISRN Oncol       Date:  2012-03-11

8.  Delivery of Anti-microRNA-712 to Inflamed Endothelial Cells Using Poly(β-amino ester) Nanoparticles Conjugated with VCAM-1 Targeting Peptide.

Authors:  Pere Dosta; Ian Tamargo; Victor Ramos; Sandeep Kumar; Dong Won Kang; Salvador Borrós; Hanjoong Jo
Journal:  Adv Healthc Mater       Date:  2021-01-14       Impact factor: 11.092

9.  Inhibition of lung tumor growth in nude mice by siRNACD31 targeting PECAM-1.

Authors:  Jin-Sheng Ouyang; Yu-Ping Li; Cheng-Shui Chen; Jun-Jie Chen; Tong-Ke Chen; Chang Cai; Li Yang
Journal:  Oncol Lett       Date:  2014-04-25       Impact factor: 2.967

10.  Therapeutic siRNA targeting endothelial KDR decreases portosystemic collateralization in portal hypertension.

Authors:  Javier Gallego; Ester Garcia-Pras; Marc Mejias; Nuria Pell; Ute Schaeper; Mercedes Fernandez
Journal:  Sci Rep       Date:  2017-11-01       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.